埃德蒙顿症状评估量表在针灸治疗癌痛患者中的应用:基于肿瘤科住院患者的回顾性分析和一项前瞻性预试验Application of Edmonton symptom assessment system in daily cancer pain management by acupuncture:retrospective analysis of data from an inpatient oncology department and a pilot prospective study

作者：陈耿杭; 范美玉; 常雪松; 吴泽霞; 张海波; 郭新峰; 何怡瀚

来源：World Journal of Acupuncture-Moxibustion, 2023, (1): 51-57.

• Cancer pain
• Edmonton Symptom Assessment System
• (ESAS)
• Acupuncture
• Integrative oncology
• Numerical rating scale(NRS)

Background:As pain is the most prominent clinical symptom for cancer patients and closely related to other symptoms,it is necessary to have a comprehensive assessment on promising intervention to improve pain management.Methods:A retrospective study of 489 inpatient cancer patients(1081 visits)was conducted by query-ing the electronic medical record database to test the reliability and validity of the Edmonton Symptom Assessment System.Data from a pilot prospective randomized controlled study on acupuncture for can-cer pain was analyzed to validate the Edmonton Symptom Assessment System(ESAS)as the primary outcome in the integrative oncology research.Results:In the retrospective analysis,scores of the numerical rating scale(NRS)and the ESAS total score were significantly correlated(r=0.15,P=0.02),and the correlation coefficient between NRS and pain sub-scale in ESAS was 0.47(P＜0.001).The pilot study showed the proportions of participants experi-encing more than a 2-point reduction in NRS at the end of the treatment were 80％(n=12/15)in the acupuncture group and 50％(n=7/14)in the control group,without a significant difference between groups(P=0.13).For the total scores of ESAS,more responders were found in the acupuncture group(n=13/15)compared to that in the control group(n=7/14),with no significant difference between groups(P=0.05).Conclusions:ESAS is suitable for the comprehensive assessment in patients with cancer pain and could be an appropriate outcome measurement in acupuncture research for cancer pain.Trial registration:Registered on 09/07/2018 with ChiCTR1800017023()